Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20370340 | 0.87 | POLB (0.48) | POLBHSD17B10NPC1RAB9AMAPT | |
| SCHEMBL20358372 | 0.83 | NPC1 (0.69) | POLBHSD17B10NPC1RAB9AMAPT | |
| SCHEMBL20374485 | 0.82 | NPC1 (0.55) | POLBHSD17B10NPC1RAB9AMAPT | |
| SCHEMBL20392028 | 0.80 | NPC1 (0.69) | POLBHSD17B10NPC1RAB9AMAPT | |
| SCHEMBL20374586 | 0.79 | NPC1 (0.48) | POLBHSD17B10NPC1RAB9AMAPT | |
| SCHEMBL20374476 | 0.78 | SETD7 (0.50) | POLBHSD17B10MAPTKMT2AALDH1A1 | |
| SCHEMBL20370323 | 0.78 | NPC1 (0.70) | NPC1RAB9AMAPTHPGDKMT2A | |
| SCHEMBL1515973 | 0.78 | NPC1 (0.70) | NPC1RAB9AMAPTHPGDKMT2A | |
| SCHEMBL20374432 | 0.77 | NPC1 (0.63) | POLBNPC1RAB9AHPGDKDM4E | |
| SCHEMBL20370330 | 0.77 | NPC1 (0.63) | POLBHSD17B10NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074861-A1 | Anticonvulsant Compounds | OWEN BARRY PHARMACEUTICALS INC (CA) | 2025-03-06 | — | — | US | disclosed |
| US-11952338-B2 | Anticonvulsant compounds | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2024-04-09 | — | — | US | disclosed |
| US-11345652-B2 | Anticonvulsant compounds | OWEN-BARRY PHARMACEUTICALS (CA) | 2022-05-31 | — | — | US | disclosed |
| US-11345652-B2 | Anticonvulsant compounds | OWEN-BARRY PHARMACEUTICALS (CA) | 2022-05-31 | — | — | US | disclosed |
| US-20210017116-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2021-01-21 | — | — | US | disclosed |
| US-20210017116-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2021-01-21 | — | — | US | disclosed |
| US-20200148623-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2020-05-14 | — | — | US | disclosed |
| US-20200148623-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2020-05-14 | — | — | US | disclosed |
| US-10556853-B2 | Anticonvulsant compounds | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2020-02-11 | — | — | US | disclosed |
| US-10556853-B2 | Anticonvulsant compounds | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2020-02-11 | — | — | US | disclosed |
| WO-2018129609-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2018-07-19 | — | — | WO | disclosed |
| US-20180194715-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2018-07-12 | — | — | US | disclosed |
| US-20180194715-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2018-07-12 | — | — | US | disclosed |
| US-20180194715-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952338-B2 | Anticonvulsant compounds | GABRE, CACNA1B, GRIK5 | POLB 4529/4885HSD17B10 1259/4885NPC1 1283/4885 |
| US-20180194715-A1 | ANTICONVULSANT COMPOUNDS | GABRE, CACNA1B, GRIK5 | POLB 4529/4885HSD17B10 1259/4885NPC1 1283/4885 |
| US-20210017116-A1 | ANTICONVULSANT COMPOUNDS | GABRE, CACNA1B, GRIK5 | POLB 4529/4885HSD17B10 1259/4885NPC1 1283/4885 |
| US-20200148623-A1 | ANTICONVULSANT COMPOUNDS | GABRE, CACNA1B, GRIK5 | POLB 4529/4885HSD17B10 1259/4885NPC1 1283/4885 |
| US-11345652-B2 | Anticonvulsant compounds | GABRE, CACNA1B, GRIK5 | POLB 4529/4885HSD17B10 1259/4885NPC1 1283/4885 |
| US-20250074861-A1 | Anticonvulsant Compounds | GABRE, CACNA1B, GRIK5 | POLB 4529/4885HSD17B10 1259/4885NPC1 1283/4885 |
| US-10556853-B2 | Anticonvulsant compounds | GABRE, CACNA1B, GRIK5 | POLB 4529/4885HSD17B10 1259/4885NPC1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.